CoQ10 Liposomal Delivery for Apoptosis Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in effectively reactivating p53 and modulating the Bcl-2 protein family to induce apoptosis in cancer cells, particularly due to mutations and overexpression of Bcl-2, leading to resistance to cell death and chemotherapeutic approaches.
Innovation Solution
A method involving the delivery of CoQ10 or its metabolites in liposomal formulations that form complexes with endogenous lipids, activating p53 and modulating the Bcl-2 family to initiate apoptosis in cancer cells, using compositions including CoQ10 and phospholipid liposomes with a pharmaceutically acceptable carrier, administered topically or intravenously to induce therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If p53 is reactivated and Bcl-2 is targeted to induce apoptosis, then cancer cell death is promoted, but resistance develops due to Bcl-2 overexpression and mutations
Solution Approach 1:
The patent changes the concentration and formulation parameters of CoQ10 delivery to overcome Bcl-2 mediated resistance. By using liposomal formulations with specific CoQ10 concentrations and delivery methods, the system achieves sufficient intracellular accumulation to downregulate Bcl-2 expression and reactivate p53, thereby inducing apoptosis despite resistance mechanisms
Solution Approach 2:
The patent employs composite liposomal formulations combining CoQ10 with phospholipids and other components to enhance delivery efficiency. This composite approach allows the system to penetrate cancer cell membranes effectively, deliver sufficient CoQ10 to modulate Bcl-2 family proteins, and overcome resistance while maintaining selective toxicity toward cancer cells
2Reliability
If high doses of chemotherapeutic agents are used to overcome resistance, then apoptosis induction improves, but toxicity to healthy cells increases
Solution Approach 1:
The patent uses liposomes as intermediary carriers to deliver CoQ10 selectively to cancer cells. The liposomal formulation acts as a mediator that protects healthy cells from direct exposure to high concentrations of the active compound while enabling sufficient accumulation in cancer cells through enhanced permeability and retention effects, thereby achieving therapeutic efficacy with reduced systemic toxicity
Solution Approach 2:
The patent achieves local concentration of CoQ10 at the cancer cell site through targeted liposomal delivery. By concentrating the therapeutic agent specifically where needed (in cancer cells with compromised membranes and high metabolic activity), the system achieves effective apoptosis induction without exposing healthy tissues to toxic levels of the compound
3Reliability
If Bcl-2 protein levels are reduced to induce apoptosis, then cancer cell death increases, but tumor angiogenesis and proliferation may be enhanced as compensatory mechanisms
Solution Approach 1:
The patent employs preliminary action by using liposomal CoQ10 to pre-condition cancer cells before they can activate compensatory survival mechanisms. The sustained delivery of CoQ10 via liposomes ensures continuous downregulation of Bcl-2 and activation of p53, preventing the tumor from mounting effective angiogenic or proliferative responses that would otherwise compensate for apoptosis induction
Data Source
AI summary
The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.